title: Short-term complications of intravitreal injection of triamcinolone acetonide.
abstract: OBJECTIVE
  To describe the short-term complications associated with intravitreal triamcinolone acetonide (IVTA) injection in the treatment of posterior segment disorders.
  
  
  METHODS
  The medical records of 784 patients (929 consecutive eyes) were retrospectively reviewed at a single institution. One or more IVTA injections for treatment of a variety of steroid-responsive posterior segment disorders (predominantly diabetic macular edema, choroidal neovascularization, and retinal venous occlusions) were administered. Adverse events occurring within 3 months of the initial injection were identified.
  
  
  RESULTS
  The most common adverse event occurring within 3 months after the initial injection was steroid-related ocular hypertension, with intraocular pressure spikes of >21 mm Hg in 21% of eyes and >25 mm Hg in 11% of eyes. Ocular inflammation occurred in six eyes (0.6%): four eyes with sterile hypopyon and two eyes without hypopyon. Three eyes (0.3%) had corneal epithelial defects thought to be related to pretreatment with povidone-iodine solution. No eyes had culture-positive infectious endophthalmitis. Cataract progression was not assessed in this analysis.
  
  
  CONCLUSIONS
  IVTA injection for the treatment of steroid-responsive disorders of the posterior segment, when administered under sterile conditions, is associated with a low incidence of serious vision-threatening adverse events within the first 3 months after injection.
authors.affiliation: Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. rothretina@gmail.com
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Roth
authors.forename: Tony
authors.initials: T
authors.lastname: Realini
authors.forename: William J
authors.initials: WJ
authors.lastname: Feuer
authors.forename: Ravi
authors.initials: R
authors.lastname: Radhakrishnan
authors.forename: Jonathan
authors.initials: J
authors.lastname: Gloth
authors.forename: Mark R
authors.initials: MR
authors.lastname: Heimmel
authors.forename: Robert D
authors.initials: RD
authors.lastname: Fechtner
authors.forename: David L
authors.initials: DL
authors.lastname: Yarian
authors.forename: Stuart N
authors.initials: SN
authors.lastname: Green
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D015862:Choroid Diseases / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced; D012164:Retinal Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide